A wide array of drugs is available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially alendronate, dominate first-line treatment, mainly because of the drug class’s widespread generic availability and physician familiarity. Branded agents like Amgen’s Prolia and Evenity as well as Radius Health’s Tymlos are reserved for high-risk patients, primarily because of their high prices. This report presents insight into the treatment of a disease in which brands compete for market share in the second and later lines of therapy and monotherapy is preferred.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Eli Lilly, Radius Health, Amgen.
Key drugs: Oral bisphosphonates, zoledronate, Prolia, teriparatide, Tymlos, Evenity.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.